Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Matrai CE, Ohara K, Eng KW, Glynn SM, Chandra P, Chatterjee-Paer S, et al. Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence. Int J Gynecol Pathol. 2021.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.

Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al. Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021;4(1):785.

Zoughbi WA, Fox J, Beg S, Papp E, Hissong E, Ohara K, et al. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist. 2021.

Goyal A, Davey DD, Souers RJ, Tabbara SO, Goodrich K, Booth CN. Rescreening Practices of Negative Papanicolaou Tests With Positive Human Papillomavirus Test Result: Survey Results of Laboratories Participating in the College of American Pathologists Gynecologic Cytology (PAP Education) Program. Arch Pathol Lab Med. 2021.

Sakunrangsit N, Pholtaisong J, Sucharitakul J, Wanna-Udom S, Prombutara P, Pisitkun P, et al. Identification of candidate regulators of mandibular bone loss in FcγRIIB Mice. Sci Rep. 2021;11(1):18726.

Subrahmanian S, Borczuk A, Salvatore S, Fung K-, Merrill JT, Laurence J, et al. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J Thromb Haemost. 2021;19(9):2268-2274.

Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, et al. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. Clin Cancer Res. 2021;27(7):1855-1863.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.